Pharmaceuticals
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
SUZHOU, China, July 29, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administrat...
2021-07-29 07:46
2116
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, In...
2021-07-29 07:40
3830
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant pr...
2021-07-28 21:08
1538
Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis
HONG KONG, July 28, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European,Hong Kong andMacau approved treatment for PE receives a detailed market ass...
2021-07-28 20:05
7937
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...
2021-07-28 19:15
4320
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive...
2021-07-28 17:13
1940
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of...
2021-07-28 13:47
5082
India-based MedTel receives investment term sheet from Catalist-listed Metal Component Engineering (MCE, SGX:5DX)
SINGAPORE, July 28, 2021 /PRNewswire/ -- Catalist-listed Metal Component Engineering Limited ("MCE") is pleased to announce that it has, through its subsidiary, Metal Precision Services Pte Ltd, entered into a term sheet to take an equity stake in MedTel Healthcare Private Limited ("MedTel"). MCE...
2021-07-28 11:36
11288
More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey
* New survey demonstrates general apathy among Singaporeans towards liver health, particularly among those aged 25 and below, despite high rates of liver cancer and failure in the country * Hepatitis B causes 60-70% of total number of liver cancer cases in the country[1]; liver cancer known ...
2021-07-28 11:00
1553
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021
– Biennial Grant Program Supports Community Projects Focused on Improving Education About Liver Health inSingapore and 10 Other Countries and Territories– – Inaugural Cycle of the Grant will Focus on Hepatitis B Awareness Initiatives – SINGAPORE, July 28, 2021 /PRNewswire/ -- Gilead Sciences, I...
2021-07-28 11:00
3635
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group * Receptor oc...
2021-07-28 08:30
2520
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
SHANGHAI and GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that onJuly 27, 2021, the Board of Directors of the Comp...
2021-07-27 20:35
11413
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
* New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE™ nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure * SPL7013, the antiviral agent in V...
2021-07-27 19:53
4746
PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference
DAEJEON, South Korea, July 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmolo...
2021-07-26 20:00
1454
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumo...
2021-07-26 19:11
4669
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
2021-07-26 18:00
3338
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-26 08:00
6299
GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices
ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to contin...
2021-07-23 21:02
8702
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), aKentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will r...
2021-07-23 16:00
1691
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
2021-07-22 21:50
9267
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714